SCHEMBL14754192

SCHEMBL14754192

CCOC(=O)C1CC[C@H](C(=O)OCC)N1Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
PKM P14618 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
ATM Q13315 1/20 0.49
CCR8 P51685 1/20 0.48
POLB P06746 1/20 0.47
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10258854 1.00 ALDH1A1 (0.51) ALDH1A1MEN1KMT2APKMNPSR1
SCHEMBL5466112 1.00 ALDH1A1 (0.51) ALDH1A1MEN1KMT2APKMNPSR1
SCHEMBL3718243 1.00 ALDH1A1 (0.51) ALDH1A1MEN1KMT2APKMNPSR1
SCHEMBL11106021 1.00 ALDH1A1 (0.51) ALDH1A1MEN1KMT2APKMNPSR1
SCHEMBL9083343 1.00 ALDH1A1 (0.51) ALDH1A1MEN1KMT2APKMNPSR1
Hydrochloric Acid SCHEMBL29999389 0.98 ALDH1A1 (0.50) ALDH1A1MEN1KMT2APKMNPSR1
SCHEMBL11106907 0.96 MEN1 (0.48) ALDH1A1MEN1KMT2APKMNPSR1
SCHEMBL12479041 0.96 MEN1 (0.48) ALDH1A1MEN1KMT2APKMNPSR1
SCHEMBL12479042 0.96 MEN1 (0.48) ALDH1A1MEN1KMT2APKMNPSR1
SCHEMBL11106393 0.96 MEN1 (0.48) ALDH1A1MEN1KMT2APKMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3932917-A2 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY The Global Alliance for TB Drug Development, Inc. (US) 2022-01-05 EP disclosed
WO-2017015106-A1 SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2017-01-26 WO disclosed
US-20130059873-A1 PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) ABBVIE INC. 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059873-A1 PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) DPP4, DPP3, DPP7 ALDH1A1 2295/4885MEN1 3576/4885KMT2A 3404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.